Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "ED"

9931 News Found

EU to withdraw Levamisole medicines over risk of rare, deadly brain disorder
News | February 17, 2026

EU to withdraw Levamisole medicines over risk of rare, deadly brain disorder

The recommendation is based on new data from continuous safety monitoring of medicines in the EU


Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD
Clinical Trials | February 17, 2026

Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD

Duvakitug was well tolerated and safety was consistent with the induction study


Clinigen bags Japan's nod to human milk-based medicine for preterm infants
R&D | February 16, 2026

Clinigen bags Japan's nod to human milk-based medicine for preterm infants

PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world


Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial
Clinical Trials | February 14, 2026

Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial

PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients


DFE Pharma launches EcoLact 2030 to deliver verified CO2 cuts across pharma supply chains
Sustainability | February 13, 2026

DFE Pharma launches EcoLact 2030 to deliver verified CO2 cuts across pharma supply chains

The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio


Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics
News | February 13, 2026

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore


Lupin Q3 FY26 consolidated PAT jumped 37.4% to Rs.  1,180.5 Cr
News | February 13, 2026

Lupin Q3 FY26 consolidated PAT jumped 37.4% to Rs. 1,180.5 Cr

U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales


Alkem MedTech to acquire 55% stake in Switzerland's Occlutech for €99.4M
Medical Device | February 13, 2026

Alkem MedTech to acquire 55% stake in Switzerland's Occlutech for €99.4M

Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure